Mouse Monoclonal NPPA Antibody

NPPA (Natriuretic Peptide Precursor A) antibodies are immunological tools targeting peptides derived from the *NPPA* gene, which encodes atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). These hormones, primarily secreted by cardiac cells, regulate blood pressure, fluid balance, and cardiovascular homeostasis by promoting vasodilation, natriuresis, and diuresis. Antibodies against NPPA-derived peptides are widely used in research and diagnostics to detect, quantify, or localize ANP/BNP in tissues or biological samples. They play a critical role in studying cardiovascular diseases, such as heart failure, hypertension, and myocardial infarction, where ANP/BNP levels serve as key biomarkers for disease progression or therapeutic response. Commercially available NPPA antibodies are typically developed in hosts like rabbits or mice, using immunogenic epitopes from conserved regions of the precursor protein. Their applications span Western blotting, ELISA, immunohistochemistry, and immunofluorescence. Validation parameters, including specificity, sensitivity, and cross-reactivity, are crucial due to structural similarities among natriuretic peptide family members. Additionally, species reactivity (human, mouse, rat) is a key consideration for experimental design. Recent studies also explore their potential in targeting NPPA pathways for novel cardiovascular therapies. Quality control, such as knockout validation or peptide blocking assays, ensures reliability in both preclinical and clinical research settings.